Names under consideration

USAN Council's Statement on the Use of USAN as Domain Names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

The following names for the drugs described are "under consideration" by the USAN Council:

aflibercept
angiogenesis inhibitor

bardoxolone methyl
antineoplastic agent, anticarcinogenesis agent, cancer supportive agent, immunomodulatory, and/or anti-inflammatory agent

bexalomer
treatment of hyperphosphatemia

coleneuramide
prevention of progression in patients with diabetic neuropathy

denenicokin
treatment of cancer

efungumab
treating infections of C. Albicans

farletuzumab
treatment of cancer

fidaxomicin
antibacterial

fosbretabulin disodium
treatment of cancer and ophthalmic diseases

fostamatinib disodium
treatment of rheumatoid arthritis

gantenerumab
treatment of Alzheimer's disease

hydroxyethyl starch 130/0.4
prophylaxis of hypervolemia

ifegostat
treatment of Gaucher's disease

ilimapimod
treatment of atherosclerosis, neuropathic pain and chronic obstructive pulmonary disease

ingenol mebutate
topical treatment of actinic keratosis

ixutumumab
treatment of solid tumors

lomtapide
treatment of vitamin B folic acid deficiency

losmapimod
treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, major depressive disorder, atherosclerosis

nelotanserin
treatment of sleep disorders

pozanicline
attention-deficit hyperactivity disorder, Alzheimer's-type dementia

ramucirumab
treatment of solid tumors

rezatomidine
treatment of neuropathic pain

rintalizumab
treatment of systemic lupus erythematosus

robatumumab
treatment of cancer (inhibits insulin-like growth factor 1 receptor, IGF-1R)

saplintide
treatment of obesity and obesity-related disorders, such as diabetes

sofinicline
attention-deficit hyperactivity disorder, Alzheimer's-type dementia, diabetic neuropathy

sonedenoson
wound healing, adenosine A_2a receptor agonist

spinosad
pediculicide (human health), ecto parasiticide (animal health)

stolanezumab
treatment of Alzheimer's disease

tafamabril
treatment of transthyretin-associated amyloidosis

terofexro isopropyl
treatment of lipid disorders

tozasertib lactate
treatment of cancer

tylvalosin
veterinary antibiotic

varlitinib
antineoplastic

vatactant
lung surfactant replacement

vedolizumab
ulcerative colitis and Crohn's disease

Any comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 515 North State Street, Chicago, IL 60610, or sent via e-mail to USAN@ama-assn.org.